Global In-Vitro Toxicology Testing Market - Product Image

Global In-Vitro Toxicology Testing Market

  • ID: 3804183
  • Report
  • Region: Global
  • 127 pages
  • Mordor Intelligence
1 of 3
The global market for in-vitro toxicology testing was estimated at USD 10.8 billion in 2014. The market is projected to reach USD 19 billion by the end of 2020 at a CAGR of 9.8% during the forecast period 2014-2020.

Predictive in-vitro toxicology is the new cutting edge technology in biopharmaceutical research. It is considered one of the most significant steps in drug discovery. Predictive in-vitro toxicology is expected to improve the quality and quantity of drugs entering clinical studies. In addition, it improves the safety and efficiency of new compounds and allows compounds to be arranged early in the development process. Earlier and more lucrative identification of potential mechanisms that cause adverse drug reactions have significant potential for improving consequences in drug discovery.

Several industries require toxicity testing of their products. On the basis of end-users, the market is segmented into pharmaceutical industry, cosmetics and household products, chemicals industry and the food & beverages industry. Pharmaceutical industry has the largest market share. This is attributed to the adoption of in-vitro methods in the detection of toxic effects to curb drug development costs and initiatives such as AXLR8 program by the European Union.

Cosmetics is expected to be the fastest-growing industry in coming years with government support and amendment of European Union’s Cosmetics Directive, which has set forth a ban on the use of animals in testing for any toxic effects of beauty products.

Rapid technological advances, ban on the use of animals for testing and advances in toxicity testing protocols are the major factors driving the growth of the in-vitro toxicology testing market. On the other hand, stringent regulatory framework and the inability of in-vitro models to detect certain anomalies are the major challenges faced by the market.

The market for in-vitro toxicology testing is segmented on basis of technology, methods and applications. Technology segment is sub-divided into High Throughput Screening (HTS), molecular imaging, cell culture, genomics, toxicogenomics, proteomics and metabolomics. In-vitro testing includes the following methods namely, cell-based assay, biochemical-based assay, in-silico-based and ex vivo-based methods. The application segment is further categorized into acute systemic toxicity, dermal toxicity, ocular toxicity pharmacokinetics & metabolism, organ-specific toxicity, reproductive/developmental toxicity and others.

Based on geography, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World. Currently, Europe is the largest market for in-vitro toxicology testing, owing to the high prevalence of cosmetic product testing and government support, followed by North America. Asia-Pacific is the fastest-growing region. The emerging countries in the region such as China and India are expected to register moderately high growth rates compared to previous years because of low development costs and increase in investments.

Several players in this market are trying to expand their product portfolio in order to compete in the global market. Top companies are expanding their growth in this market by acquiring other companies while few others are using acquisition as a market entry strategy. The dominant players in this market are Agilent Technologies, Alere Inc., Bio-Rad, Sigma-Aldrich, Catalent Pharma Solutions, Charles River Laboratories, Covance, Cyprotex, Eurofins Scientific Inc., GE Healthcare, Thermo Fisher Scientific and Quest Diagnostics.

Please note: As this product is updated at the time of order, dispatch will be 72 hours from the date the order and full payment is received.
READ MORE
Note: Product cover images may vary from those shown
2 of 3
1. Introduction
1.1 Report Description
1.2 Research Approach And Methodology
1.2.1 Introduction
1.2.2 Research Design
2. Key Deliverables
3. Executive Summary
4. Market Dynamics
4.1 Market Segmentation
4.2 Market Drivers
4.2.1 Consensus Against Using Animals In Testing Procedures
4.2.2 Rapid Advances In Technologies Boosting The Market Growth
4.2.3 Advances In Toxicity Testing Protocols
4.3 Market Restraints
4.2.1 The Inability Of In-Vitro Models To Detect Certain Anomalies
4.3.3 Stringent Regulatory Framework
4.3.2 Limitations Of In-Vitro Toxicology Testing
5. Market Segmentation
5.1 By End User
5.1.1 Pharmaceuticals
5.1.2 Food Industry
5.1.3 Chemicals Industry
5.1.4 Cosmetics
5.1.5 Diagnostics
5.1.6 Others
5.2 By Mode Of Administration
5.2.1 Dermal
5.2.2 Oral
5.2.3 Occular
5.2.4 Inhalation
5.2.5 Infusion
5.2.6 Rectal Administration
5.2.7 Parenteral Administration
5.2.8 Intra-Arterial Administration
5.2.9 Intra-Nasal Administration
5.3 By Technology
5.3.1 High-Through Put Screening
5.3.2 Molecular Imaging
5.3.3 Cell Culture
5.3.4 Omics
5.3.4.1 Genomics
5.3.4.2 Toxicogenomics
5.3.4.3 Proteomics
5.3.4.4 Metabolomics
5.3.4.5 Others
5.4 By Method
5.4.1 Cell-Based Assay
5.4.2 Biochemical-Based Assay
5.4.3 In-Silico-Based
5.4.4 Ex Vivo-Based Methods
5.4.5 Others
5.5 Segmentation By Geography
5.5.1 North America
5.5.1.1 Usa
5.5.1.2 Canada
5.5.1.3 Mexico
5.5.2 Europe
5.5.2.1 Uk
5.5.2.2 Germany
5.5.2.3 France
5.5.2.4 Spain
5.5.2.5 Italy
5.5.2.6 Rest Of Europe
5.5.3 Asia-Pacific
5.5.3.1 China
5.5.3.2 Japan
5.5.3.3 India
5.5.3.4 South Korea
5.5.3.5 Rest Of Asia-Pacific
5.5.4 Rest Of The World
6. Competitive Landscape
6.1 Mergers & Acquisitions
6.2 Agreements, Collaborations & Partnerships
6.3 New Product Launches
6.4 Recommendations To New Market Players:
7. Company Profiles
7.1 Sigma-Aldrich Fine Chemicals
7.1.1 Business Overview:
7.1.1 Products & Services:
7.1.1 Financials:
7.2 Biovia Corporation
7.2.1 Business Overview:
7.2.2 Products & Services
7.3 Agilent Technologies
7.3.1 Business Overview:
7.3.1 Products & Services:
7.3.1 Financials:
7.4 Charles River Laboratories
7.4.1 Business Overview
7.4.2 Products & Services
7.4.3 Financials
7.5 Covance Incorporated
7.5.1 Business Overview
7.5.2 Products & Services
7.5.3 Financials
7.6 Ge Healthcare
7.6.1 Business Overview
7.6.2 Products & Services
7.6.3 Financials
7.7 Thermo Fisher Scientific Inc.
7.7.1 Business Overview:
7.7.2 Products And Services:
7.7.3 Financials:
7.8 Quest Diagnostics Inc.
7.8.1 Business Overview:
7.8.2 Products And Services:
7.8.3 Financials:
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
Note: Product cover images may vary from those shown
Adroll
adroll